Study of a new drug for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancer types: kidney cancer (clear cell or papillary), ovarian cancer (endometrioid type), uterine cancer (endometrioid type), colorectal cancer (adenocarcinoma), or lung cancer (adenocarcinoma).
- Your cancer has spread to other parts of the body or cannot be removed by surgery.
- You are well enough to perform daily activities (ECOG score 0 or 1).
- You must provide a sample of your tumor tissue from a previous surgery or biopsy for testing.
- You do not have active brain metastases, though treated and stable brain spots may be allowed.
- You have not had a bowel blockage within the last 30 days that required a hospital stay.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, JNJ-87704916, given alone or with other treatments for people with advanced solid tumors that have stopped responding to standard therapies. It may be an option if you have a tumor that can be injected and are in good overall health.
This early-stage trial tests a new drug called JNJ-1761981 in people with solid tumors (cancers that form in organs or tissues, excluding brain tumors) that have spread or returned after standard treatment. The study aims to find the right dose and see how well the drug works.
This trial tests a new drug that targets a protein called MET found on some cancer cells. It may help people with certain advanced cancers that have not responded to other treatments.
This trial tests an experimental drug for people with advanced solid tumors or lymphoma that has not responded to standard treatments and has a specific genetic change (loss of MTAP or CDKN2A genes). The drug is taken by mouth and may work by targeting cancer cells with this change.
This trial is testing a new drug called OTP-01 that targets two proteins (PD-1 and VEGFR2) to help your immune system fight cancer and stop tumors from growing. It is for people with advanced solid tumors that have not responded to or cannot have standard treatments.
This trial tests a new drug called JNJ-89862175 for people with certain advanced solid tumors, including lung adenocarcinoma, kidney cancer, ovarian cancer, and uterine cancer. The goal is to see if this treatment is safe and effective.
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.